Abstract-In 2017, the American College of Cardiology/American Heart Association (ACC/AHA) and the American College of Physicians/American Academy of Family Physicians (ACP/AAFP) published blood pressure guidelines. Adults recommended antihypertensive medication initiation or intensification by the ACP/AAFP guideline receive the same recommendation from the ACC/AHA guideline. However, many adults ≥60 years old are recommended to initiate or intensify antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline. We compared atherosclerotic cardiovascular disease event rates according to antihypertensive treatment recommendations in the ACC/AHA and ACP/AAFP guidelines among adults ≥60 years old with systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg in the REGARDS study (Reasons for Geographic and Racial Differences in Stroke) and the JHS (Jackson Heart Study). Among 4311 participants not taking antihypertensive medication at baseline, 11.4%, 61.2%, and 27.4% were recommended antihypertensive medication initiation by neither guideline, the ACC/AHA but not the ACP/AAFP guideline, and both guidelines, respectively. Atherosclerotic cardiovascular disease event rates (95% CI) for these groups were 3.4 (1. 
I
n March 2017, the American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) published a guideline for the treatment of hypertension in adults ≥60 years of age. 1 Initiation of antihypertensive medication is recommended by the ACP/AAFP guideline for adults ≥60 years of age with systolic blood pressure (SBP) ≥150 mm Hg or with SBP ≥140 mm Hg among those with high cardiovascular risk based on an individualized assessment (eg, based on the presence of diabetes mellitus, known vascular disease, prior stroke or transient ischemic attack, metabolic syndrome, chronic kidney disease, or for older adults). For adults ≥60 years of age taking antihypertensive medication, treatment intensification is recommended to achieve an SBP goal <150 mm Hg (<140 mm Hg for those with high cardiovascular risk).
In November 2017, the American College of Cardiology (ACC) and the American Heart Association (AHA) published a guideline for classification of blood pressure (BP) and February 2019 treatment of high BP in adults of all ages, including those ≥60 years of age. 2 Initiation of antihypertensive medication is recommended by the ACC/AHA guideline for adults with SBP ≥140 mm Hg or diastolic BP (DBP) ≥90 mm Hg. Additionally, initiation of antihypertensive medication is recommended for adults with SBP of 130 to 139 mm Hg or DBP of 80 to 89 mm Hg who have high cardiovascular risk (ie, those with a history of cardiovascular disease [CVD], a 10-year predicted atherosclerotic CVD [ASCVD] risk ≥10%, diabetes mellitus, chronic kidney disease, or age ≥65 years with an SBP ≥130 mm Hg). Treatment intensification is recommended to achieve an SBP goal <130 mm Hg. A DBP goal of <80 mm Hg is set for adults with <65 years of age or with high CVD risk.
All adults recommended antihypertensive medication initiation or intensification by the ACP/AAFP guideline are also recommended treatment initiation or intensification by the ACC/AHA guideline. However, based on differences in the ACC/AHA and ACP/AAFP guidelines, many adults ≥60 years of age may be recommended to initiate or intensify antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline. 3 In the current study, we determined the percentage of adults ≥60 years of age for whom initiation or intensification of antihypertensive medication is recommended by neither the ACC/AHA nor the ACP/AAFP guideline, by the ACC/AHA but not the ACP/AAFP guideline, and by both guidelines. Additionally, we estimated the rates of ASCVD events and all-cause mortality among adults ≥60 years of age in these 3 groups. To accomplish these aims, we analyzed data from the REGARDS study (Reasons for Geographic and Racial Differences in Stroke) and the JHS (Jackson Heart Study).
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Methods
Requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be submitted to the REGARDS and JHS executive committees at https://www.jacksonheartstudy.org and http://regardsstudy.org, respectively.
Study Populations
The REGARDS study was designed to investigate reasons underlying the higher rate of stroke mortality among blacks compared with whites and among residents of the Southeastern United States compared with other US regions. 4 A total of 30 239 adults from all 48 contiguous US states and the District of Columbia were enrolled between January 2003 and October 2007. The JHS is a populationbased prospective cohort study designed to examine the cause of CVD and related risk factors among blacks. 5 For the JHS, 5306 black adults were recruited from the Jackson, Mississippi metropolitan area between 2000 and 2004. We excluded participants from each study who were (1) <60 years of age, (2) had SBP <130 mm Hg and DBP <80 mm Hg, or (3) were missing data on antihypertensive medication use, BP, or other variables used to determine high CVD risk according to the ACC/AHA or ACP/AAFP guideline. Participants with SBP <130 mm Hg and DBP <80 mm Hg were excluded because no adults with BP in this range are recommended initiation or intensification of antihypertensive medication by either the ACC/AHA guideline or the ACP/AAFP guideline. After these exclusions, data were available from 11 682 participants (n=10 616 REGARDS participants and n=1066 JHS participants) for the current analysis (Figures S1 and S2 in the online-only Data Supplement, respectively). Conduct of the REGARDS study and JHS were approved by institutional review boards at the participating institutions and conduct of the current analysis was approved by the Institutional Review Board at the University of Alabama at Birmingham. All participants provided written informed consent at baseline.
Study Variables
Information on age, sex, race, education, cigarette smoking, and history of myocardial infarction or stroke was collected at baseline by self-administered questionnaire for JHS participants and by computer-assisted telephone interviews for REGARDS study participants. Height and weight were measured during each study's baseline visit and used to calculate body mass index. Blood and urine specimens collected at each study's baseline visit were used to measure total and HDL (high-density lipoprotein) cholesterol, serum creatinine, serum glucose, and urinary albumin-to-creatinine ratio. [6] [7] [8] [9] Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. 10 Albuminuria was defined as an albumin-to-creatinine ratio of ≥30 mg/g. Diabetes mellitus was defined as a fasting serum glucose ≥126 mg/dL, nonfasting serum glucose ≥200 mg/dL, or self-report of a prior diagnosis with glucose-lowering medication use (insulin or oral hypoglycemic medication). 11 Glycosylated hemoglobin A1c was measured in the JHS, and participants with glycosylated hemoglobin A1c ≥48 mmol/ mol (≥6.5%) were considered to have diabetes mellitus. In both studies, participants completed an ECG during the baseline study visit. A history of CVD was defined as a history of stroke, heart failure, or myocardial infarction at baseline. REGARDS study participants with a history of coronary revascularization were also considered to have a history of CVD. Coronary revascularization was not assessed at baseline in the JHS. For participants without a history of CVD, 10-year predicted ASCVD risk was calculated using the Pooled Cohort risk equations.
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BP Measurement
In both the REGARDS study and the JHS, each participant had their SBP and DBP measured twice after a 5-minute seated rest. BP was measured using an aneroid sphygmomanometer (American Diagnostic Corporation, Hauppauge, NY) in the REGARDS study and using a Hawksley random-zero sphygmomanometer (Hawksley and Sons, Ltd, Lancing, United Kingdom) in JHS. As previously described, the random-zero BP measurements in JHS were calibrated to an oscillometric device using robust regression.
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Hypertension Guideline Recommendations
Recommendations for initiation or intensification of antihypertensive medication were defined according to the ACC/AHA and ACP/AAFP guidelines ( Figure) . Participants not taking antihypertensive medication at baseline were categorized into 1 of 3 mutually exclusive treatment initiation groups: those recommended initiation of antihypertensive medication by (1) neither guideline, (2) the ACC/AHA but not the ACP/AAFP guideline, or (3) both guidelines. Participants taking antihypertensive medication at baseline were categorized into 1 of 3 mutually exclusive treatment intensification groups: those who were recommended intensification of antihypertensive medication by (1) neither guideline, (2) the ACC/AHA but not the ACP/AAFP guideline, or (3) both guidelines. As only 66 participants with SBP ≥130 mm Hg or DBP ≥80 mm Hg taking antihypertensive medication were not recommended for intensification of antihypertensive medication by either guideline, this group was not analyzed.
ASCVD Events and All-Cause Mortality
The primary outcome for the current study was ASCVD, defined by a stroke or coronary heart disease during follow-up. Descriptions of the adjudication process in the REGARDS study and JHS have been published. 6, 14, 15 Participants or their proxies were contacted to identify hospitalizations and possible ASCVD events at 6-month intervals in the REGARDS study and annually in the JHS. When potential events were identified, medical records were retrieved, and events were adjudicated by trained physicians. All-cause mortality was evaluated as a secondary outcome. Deaths were detected by reports from next of kin, the National Death Index, or through online resources (eg, Social Security Death Index). Follow-up for the current analysis was available through December 31, 2014, for REGARDS study participants and December 31, 2012, for JHS participants.
Statistical Analysis
We calculated baseline characteristics for participants in the 3 treatment initiation groups. The cumulative incidence and incidence rates for ASCVD and all-cause mortality, separately, were computed for participants in these 3 groups, overall and after stratification by age (60-<75 years and ≥75 years), race (white and black), and sex (women and men). We computed hazard ratios for ASCVD and all-cause mortality with multivariable adjustment using 3 nested models, with participants not recommended initiation of antihypertensive medication by either guideline serving as the referent group. In model 1, hazard ratios were adjusted for enrollment in the JHS or REGARDS study. Model 2 included adjustment for variables in model 1 and age, sex, and race. Model 3 included adjustment for variables in model 2 and education, smoking habits, diabetes mellitus, estimated glomerular filtration rate <60 mL/(min·1.73 m 2 ), body mass index, albumin-to-creatinine ratio ≥30 mg/g, total cholesterol, HDL, and history of ASCVD events (ie, stroke or coronary heart disease). Hazard ratios were also calculated for participants who were recommended for initiation of antihypertensive medication by both guidelines versus those recommended initiation of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline. For participants who were taking antihypertensive medication at baseline, the above analyses were repeated, comparing those who were recommended intensification of antihypertensive medication by the ACC/AHA but not the ACP/ AAFP guideline to those who were recommended intensification by both guidelines. For the analysis of intensification of antihypertensive medication, model 3 included the variables listed above and the number of classes of antihypertensive medications being taken at baseline. The cumulative incidence and hazard ratio calculations for ASCVD events took into account the competing risk for mortality. 16 Participants contributed time at risk for ASCVD from baseline until their first adjudicated ASCVD event, death, or end of follow-up, whichever occurred earliest. For mortality, participants contributed time at risk from baseline through their death or end of follow-up, whichever occurred earliest. Analyses were conducted using R version 3.5.0 and SAS version 9.4. However, based on differences in the ACC/AHA and ACP/AAFP guidelines, many adults ≥60 y of age may be recommended to initiate or intensify antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline. †At this level of systolic blood pressure, no one is recommended for antihypertensive medication initiation or intensification by neither guideline. ‡At this level of systolic blood pressure, no one is recommended for antihypertensive medication initiation or intensification by the ACC/AHA but not the ACP/AAFP guideline. §At this level of systolic blood pressure, no one is recommended for antihypertensive medication initiation or intensification by both guidelines. ||10-year risk of atherosclerotic cardiovascular disease represents the risk for coronary heart disease or stroke event within 10-year and was calculated using the Pooled Cohort risk equations. ¶For the current study, known vascular disease included history of myocardial infarction, stroke, or coronary revascularization. ACR indicates albumin-to-creatinine ratio; ASCVD, atherosclerotic CVD; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; and TIA, transient ischemic attack.
Results
Initiation of Antihypertensive Medication
Among 4311 participants not taking antihypertensive medication at baseline with SBP ≥130 or DBP ≥80 mm Hg, 11.4% were not recommended initiation of antihypertensive medication by either the ACC/AHA or the ACP/AAFP guideline, 61.2% were recommended initiation of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline, and 27.4% were recommended initiation of antihypertensive medication by both guidelines. Characteristics of the participants in these 3 groups are presented in Table 1 . The mean 10-year predicted ASCVD risk (and % of participants with risk ≥10%) was 6.4% (0%), 18.7% (87.7%), and 25.8% (91.8%) among participants who were not recommended initiation of antihypertensive medication by either guideline, recommended initiation of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline, and recommended initiation of antihypertensive medication by both guidelines, respectively. Over 12.2 years of follow-up, there were 592 ASCVD events and 1075 deaths among participants not taking antihypertensive medication at baseline. The cumulative incidence of ASCVD and all-cause mortality were higher among participants who were recommended initiation of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline or by both guidelines compared with their counterparts who were not recommended initiation of antihypertensive medication by either guideline ( Figure S3 ). After adjustment for study (ie, JHS or REGARDS study), participants who were recommended initiation of antihypertensive medication by the ACC/ AHA but not the ACP/AAFP guideline and by both guidelines were 5.00 (95% CI, 2.94-8.52) and 6.95 (95% CI, 4.05-11.91) times more likely, respectively, to have an ASCVD event compared with their counterparts who were not recommended initiation of antihypertensive medication by either guideline (Table 2) . Participants who were recommended for initiation of antihypertensive medication by the ACC/AHA but not the ACP/ AAFP guideline and by both guidelines were 5.62 (95% CI, 3.71-8.52) and 8.58 (95% CI, 5.64-13.07) times more likely, respectively, to die compared with their counterparts who were not recommended initiation of antihypertensive medication by either guideline. These associations remained statistically significant after multivariable adjustment. Higher ASCVD and mortality rates were present among participants recommended initiation of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline and both guidelines compared with their counterparts not recommended initiation of antihypertensive medication by either guideline in subgroups defined by age, race, and sex (Table S1 ). The hazard ratio for ASCVD events and all-cause mortality adjusted for enrollment in the JHS or REGARDS study among participants who were recommended for initiation of antihypertensive medication by both guidelines compared with their counterparts who were recommended for initiation by the ACC/AHA but not the ACP/AAFP guideline was 1.39 (95% CI, 1.17-1.64) and 1.53 (95% CI, 1.35-1.73), respectively.
Intensification of Antihypertensive Medication
Among 7281 participants taking antihypertensive medication at baseline with SBP ≥130 or DBP ≥80 mm Hg, 57.9% and 42.1% were recommended intensification of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline and by both guidelines, respectively. The mean 10-year predicted ASCVD risk was 20.8% and 31.4% among participants who were recommended intensification of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline and by both guidelines, respectively (Table 3) .
Over 12.2 years of follow-up, there were 1258 ASCVD events and 2194 deaths among participants taking antihypertensive medication. The cumulative incidence of ‡Albuminuria was defined as an albumin-to-creatinine ratio of ≥30 mg/g. §Ten-year predicted atherosclerotic cardiovascular disease risk was calculated for participants without a history of cardiovascular disease using the Pooled Cohort risk equations.
ASCVD events and all-cause mortality was higher among participants recommended for antihypertensive medication intensification by both the ACC/AHA and ACP/AAFP guidelines compared with their counterparts recommended for intensification by the ACC/AHA but not the ACP/AAFP guideline ( Figure S4 ). These associations remained statistically significant after multivariable adjustment (Table 4) . Results were consistent in subgroups defined by age, race, and sex (Table S2) .
Discussion
In the current analysis, 61.2% of adults ≥60 years of age with SBP ≥130 mm Hg or DBP ≥80 mm Hg not taking antihypertensive medication at baseline were recommended for initiation of antihypertensive medication by the ACC/AHA guideline but not by the ACP/AAFP guideline. The ASCVD and mortality event rates were approximately 5× higher among this group compared with those not recommended for initiation of antihypertensive medication by either guideline. For participants taking antihypertensive medication at baseline, the ASCVD event rate was higher among those recommended for intensification of antihypertensive medication by both the ACC/AHA and ACP/AAFP guidelines versus their counterparts recommended for intensification of antihypertensive medication by the ACC/AHA but not the ACP/ AAFP indicates American Academy of Family Physicians; ACC, American College of Cardiology; ACP, American College of Physicians; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; JHS, Jackson Heart Study; and REGARDS, Reasons for Geographic and Racial Differences in Stroke study.
* Table restricted to participants not taking antihypertensive medication at baseline. †Model 1 includes adjustment for enrollment in the JHS or REGARDS study. Model 2 includes adjustment for variables in model 1 plus age, sex, and race. Model 3 includes adjustment for variables in model 2 plus education, smoking habits, diabetes mellitus, estimated glomerular filtration rate <60 mL/(min·1.73 m 2 ), body mass index, albumin-to-creatinine ratio ≥30 mg/g, total cholesterol, high-density lipoproteins, and history of atherosclerotic cardiovascular disease events (ie, stroke or coronary heart disease). ‡Albuminuria was defined as an albumin-to-creatinine ratio of ≥30 mg/g. §Ten-year predicted atherosclerotic cardiovascular disease risk was calculated for participants without a history of CVD using the Pooled Cohort risk equations.
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AAFP guideline. Based on these data, adults recommended initiation or intensification of antihypertensive medication by both guidelines are expected to experience greater absolute ASCVD and all-cause mortality risk reduction compared with adults recommended initiation or intensification of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline. However, the ASCVD and all-cause mortality event rates were high in both of these groups. There are 3 differences in the ACC/AHA and ACP/AAFP guidelines that may explain why a higher proportion of adults with ≥60 years of age are recommended for antihypertensive medication initiation and intensification by the ACC/AHA but not the ACP/AAFP guideline and why this group has high ASCVD and mortality event rates. First, the ACC/AHA guideline recommends a lower SBP threshold for treatment initiation and a lower BP treatment goal than the ACP/AAFP guideline. Using data from randomized controlled trials, an independent review committee assembled by the ACC/AHA guideline writing committee found that treatment to a SBP goal <130 mm Hg versus a higher goal was associated with a risk ratio for major CVD events of 0.83 (95% CI, 0.74-0.92), myocardial infarction of 0.85 (95% CI, 0.73-1.00), and stroke of 0.82 (95% CI, 0.70-0.96). 17 In a separate systematic review conducted for the ACP/AAFP guideline, randomization to an SBP goal of <140 mm Hg versus a higher goal was associated with risk ratio of 0.86 (95% CI, 0.69-1.06) for all-cause mortality, 0.82 (95% CI, 0.64-1.00) for cardiac events, and 0.79 (95% CI, 0.59-0.99) for stroke.
1 A meta-analysis of trials with an SBP goal <130 mm Hg versus higher goals was not reported in the ACP/AAFP guideline.
A second difference between the ACC/AHA and ACP/ AAFP guidelines is the consideration of DBP to guide antihypertensive medication initiation and intensification. The ACC/ AHA guideline recommendation to use DBP in guiding antihypertensive treatment is based on expert opinion. 2 The ACP/ AAFP stated that there was insufficient evidence to determine the benefit of antihypertensive treatment for isolated diastolic hypertension.
1 Isolated diastolic hypertension (ie, DBP but not SBP in the hypertensive range) is not a common phenotype among adults ≥60 years of age, and using DBP to guide treatment recommendations for older adults is unlikely to affect many people. 18 A third difference is the approach used to define high CVD risk. Both guidelines consider kidney disease, diabetes mellitus, and a history of CVD as conditions warranting more intensive antihypertensive treatment to achieve lower BP goals. The ACC/AHA guideline also recommends more intensive BP reduction for individuals with 10-year predicted ASCVD risk ≥10%. Studies have shown that risk equations can predict future ASVCD events more accurately compared with clinical judgment or counting the number of risk factors that are present. [19] [20] [21] In addition to antihypertensive medication, 10-year predicted ASCVD risk has been used to guide recommendations for initiation of statins and aspirin therapy. 22, 23 The decision to initiate or intensify antihypertensive medication should balance the benefits of treatment versus the potential harms. 24, 25 A meta-analysis of 11 randomized controlled trials demonstrated that antihypertensive medication provides larger absolute risk reductions at progressively higher levels of predicted ASCVD risk. 26 This suggests that adults with high predicted ASCVD risk may attain substantial absolute risk reduction by initiating or intensifying antihypertensive medication. There was no evidence of a difference in the rate of serious adverse events between participants randomized to the intensive versus standard SBP goal in the Systolic Blood Pressure Intervention Trial. 27 Also, ASCVD events can be fatal or nonfatal but severely disabling, whereas the overwhelming majority of serious adverse events are nonfatal, transient, and associated with complete recovery. 28, 29 The ACC/AHA guideline states that for older adults with a high burden of comorbidity and limited life expectancy, clinical judgment, patient preference, and a team-based approach should be applied to ), body mass index, albumin-to-creatinine ratio ≥30 mg/g, total cholesterol, HDL, history of atherosclerotic cardiovascular disease events (ie, stroke or coronary heart disease), and number of classes of antihypertensive medication taken at baseline.
assess potential risks and benefits of decisions related to initiation or intensification of antihypertensive medication. 2 Therefore, it may be appropriate for some older adults to not initiate or intensity antihypertensive medication despite meeting the BP criteria in the ACC/AHA guideline.
The current analysis has several strengths. There was substantial representation of men and women, blacks and whites, and people ≥75 years of age. Participants were followed prospectively for up to 12.2 years, and ASCVD events were adjudicated using published guidelines by trained personnel. The current analysis should be interpreted in the context of known and potential limitations. We did not have data indicating whether participants initiated or intensified antihypertensive medication during follow-up. BP levels were based on measurements obtained during a single visit. Both the ACC/AHA and ACP/AAFP guidelines recommend the diagnosis of hypertension be based on ≥2 BP measurements at ≥2 visits. The JHS and REGARDS study only included community-dwelling blacks and whites. Therefore, results may not be generalizable to people of other race groups or institutionalized adults including those in nursing homes.
Perspectives
In the current study, the ASCVD event and mortality rates were ≈5× higher among participants ≥60 years of age not taking antihypertensive medication at baseline who were recommended for treatment initiation by the ACC/AHA guideline but not the ACC/AAFP guideline compared with their counterparts who were not recommended treatment initiation by either guideline. Among participants taking antihypertensive medication at baseline, the risk for ASCVD events and all-cause mortality was high among those who were recommended for treatment intensification by the ACC/AHA guideline but not the ACP/AAFP guideline. In conclusion, the ACC/ AHA guideline directs antihypertensive medication towards a large segment of older adults who may attain substantial ASCVD risk reduction through initiation or intensification of antihypertensive medication.
